Your browser doesn't support javascript.
loading
Half of Postoperative Deaths After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Could be Preventable: A French Root Cause Analysis on 5562 Patients.
Houlzé-Laroye, Constance; Glehen, Olivier; Sgarbura, Olivia; Gayat, Etienne; Sourrouille, Isabelle; Tuech, Jean-Jacques; Delhorme, Jean-Baptiste; Dumont, Frédéric; Ceribelli, Cécilia; Amroun, Koceila; Arvieux, Catherine; Moszkowicz, David; Pirro, Nicolas; Lefevre, Jérémie H; Courvosier-Clement, Thomas; Paquette, Brice; Mariani, Pascale; Pezet, Denis; Sabbagh, Charles; Tessier, Williams; Celerier, Bertrand; Guilloit, Jean-Marc; Taibi, Abdelkader; Quenet, François; Bakrin, Naoual; Pocard, Marc; Goéré, Diane; Brigand, Cécile; Piessen, Guillaume; Eveno, Clarisse.
Afiliação
  • Houlzé-Laroye C; Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, F-59000 Lille, France.
  • Glehen O; Department of General Surgery and Surgical Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France; EMR 3738 Lyon Sud Charles Mérieux Faculty, Claude Bernard University Lyon 1, Oullins, France.
  • Sgarbura O; Department of Surgical Oncology, Cancer Institute Montpellier, University of Montpellier 208 Avenue des Apothicaires, Montpellier, Cedex 05, France.
  • Gayat E; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, F-34298, France.
  • Sourrouille I; INSERM UMR-S 942, Université de Paris, Paris, France; Department of Anaesthesiology and Critical Care Medicine, Lariboisière University Hospital, DMU PARABOL, AP-HP.Nord, Paris, France.
  • Tuech JJ; Department of Visceral and Oncological Surgery, Gustave Roussy, Cancer Campus, Villejuif Cedex, France.
  • Delhorme JB; Department of Digestive Surgery, Rouen University Hospital, Rouen, France.
  • Dumont F; Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg University, Strasbourg, France.
  • Ceribelli C; Department of Surgical Oncology, ICO René Gauducheau Cancer Center, Saint-Herblain, France.
  • Amroun K; Department of Digestive Surgery, Institut de Cancérologie de Lorraine, 54519 Vandoeuvre-les-Nancy.
  • Arvieux C; Department of General, Digestive and Endocrine Surgery, Robert-Debré Hospital, Université de Reims Champagne-Ardenne, 51100 Reims, France.
  • Moszkowicz D; Department of Digestive Surgery, Grenoble-Alpes University Hospital, Grenoble, France.
  • Pirro N; Université de Paris; Department of Digestive Surgery, Louis-Mourier Hospital, DMU ESPRIT - GHU AP-HP. Nord - University of Paris; Colombes, France.
  • Lefevre JH; Department of Digestive Surgery, Timône University Hospital, Marseille, France.
  • Courvosier-Clement T; Sorbonne Université, Department of Digestive Surgery, AP-HP, Hôpital Saint Antoine, Paris, France.
  • Paquette B; Department of Digestive Surgery, Poitiers University Hospital, Poitiers, France.
  • Mariani P; Department of Digestive and Oncologic Surgery, Liver Transplantation Unit, University Hospital of Besançon, Besançon, France.
  • Pezet D; Department of Surgical Oncology, Curie Institute, Paris, France.
  • Sabbagh C; Department of Digestive Surgery, CHU Clermont Ferrand, 1 rue Lucie et Raymond Aubrac, Clermont-Ferrand, France.
  • Tessier W; Department of Digestive and Oncological Surgery, University Hospital of Amiens, France.
  • Celerier B; Department of digestive and oncological Surgery, Oscar Lambret Center, Lille, France.
  • Guilloit JM; Department of Colorectal Surgery, CHU Bordeaux, Haut-Leveque Hospital, University of Bordeaux, Pessac, France.
  • Taibi A; Department of Surgical Oncology, François Baclesse Institute, 3 avenue du general Harris, Caen, France.
  • Quenet F; Endocrine, General and Digestive Surgery Department, CHU of Limoges, Limoges, France.
  • Bakrin N; Department of Surgical Oncology, Cancer Institute Montpellier, University of Montpellier 208 Avenue des Apothicaires, Montpellier, Cedex 05, France.
  • Pocard M; Department of General Surgery and Surgical Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France; EMR 3738 Lyon Sud Charles Mérieux Faculty, Claude Bernard University Lyon 1, Oullins, France.
  • Goéré D; Service de chirurgie digestive hépato-bilio-pancréatique, Hôpital Pitié Salpêtrière, Assistance publique-hôpitaux de Paris, AP-HP, Paris, France.
  • Brigand C; Université de Paris, UMR INSERM 1275 CAP Paris-Tech, F-75010 Paris, France.
  • Piessen G; Department of Digestive and Oncological Surgery, Saint-Louis University Hospital, Paris, France.
  • Eveno C; Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg University, Strasbourg, France.
Ann Surg ; 274(5): 797-804, 2021 11 01.
Article em En | MEDLINE | ID: mdl-34334647
OBJECTIVE: To perform a retrospective root-cause analysis of postoperative death after CRS and HIPEC procedures. BACKGROUND: The combination of CRS and HIPEC is an effective therapeutic strategy to treat peritoneal surface malignancies, however it is associated with significant postoperative mortality. METHODS: All patients treated with a combination of CRS and HIPEC between January 2009 and December 2018 in 22 French centers and died in the hospital, were retrospectively analyzed. Perioperative data of the 101 patients were collected by a local senior surgeon with a sole junior surgeon. Three independent experts investigated the typical root cause of death and provided conclusions on whether postoperative death was preventable (PREV group) or not (NON-PREV group). A typical root cause of preventable postoperative death was classified on a cause-and-effect diagram. RESULTS: Of the 5562 CRS+HIPEC procedures performed, 101 in-hospital deaths (1.8%) were identified, of which a total of 18 patients of 70 years old and above and 20 patients with ASA score of 3. Etiology of peritoneal disease was mainly colorectal. A total of 54 patients (53%) were classified in the PREV group and 47 patients (47%) in the NON-PREV group. The results of the study show that in the PREV group, WHO performance status 1-2 was more frequent and the Median Peritoneal Cancer Index was higher compared with those of the NON-PREV group. The cause of death in the PREV group was classified as: (i) preoperatively for debatable indication (59%), (ii) intraoperatively (30%) and (iii) postoperatively in 17 patients (31%). A multifactorial cause of death was found in 11 patients (20%). CONCLUSION: More than half of the postoperative deaths after combined CRS and HIPEC may be preventable, mainly by following guidelines regarding preoperative selection of the patients and adequate intraoperative decisions.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Peritoneais / Análise de Causa Fundamental / Procedimentos Cirúrgicos de Citorredução / Quimioterapia Intraperitoneal Hipertérmica Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Ann Surg Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Peritoneais / Análise de Causa Fundamental / Procedimentos Cirúrgicos de Citorredução / Quimioterapia Intraperitoneal Hipertérmica Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Ann Surg Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França